Tag:
Cardinal Health
Latest Headlines
Latest Headlines
Congress probes whether small wholesalers are gouging drug prices
Congress is investigating whether some small drug wholesalers are gaming the system by setting up their own pharmacies to get their hands on drugs in short supply.
Cardinal and McKesson positive, upbeat on financials
Drug distributors Cardinal Health ( $CAH ) and McKesson ( $MCK ) each reported positive financials for the last fiscal quarter and say they are upbeat about the future. Cardinal credits its generics
MicroPhage, Cardinal Health ink deal on MRSA test
Longmont, CO-based MicroPhage has reached an agreement granting Cardinal Health exclusive rights to market the KeyPath MRSA/MSSA blood culture test product line in North America. Under this
Specialty drugs come to Big Pharma's rescue
Specialty drugs are in the news again this week. A Reuters report quotes Sanofi CEO Chris Viehbacher ( photo ) as saying the mass market for drugs "is really starting to disappear." That's very likely
Big 3 distribs hold big pharma survival clues
Speaking of business transformation [ see related story ], an op-ed writer in Forbes says that behavior of the big three drug distributors may model behavior that big pharma can adopt during these
ABC, Cardinal see growth in specialty pharma
AmerisourceBergen CEO-in waiting Steve Collis, likely successor in July to the retiring Dave Yost, sees a future in staying the course with a focus on specialty distribution and generics. Specialty
Cardinal snaps up regional distributor for $1.3B
Big Pharma isn't the only drug-related business that's consolidating via M&A. U.S. drug distributor Cardinal Health today announced plans to buy Kinray, a smaller distributor based in the
Cardinal acquisition highlights growing specialty drug market
Cardinal Health will acquire specialty pharmaceuticals firm Healthcare Solutions Holding for $517 million in a deal that highlights the growing importance of the specialty drug sector. The
Methadone maker hits auction block
Private equity firms are circling Martindale Pharmaceuticals, the U.K.'s leading maker of methadone. Put up for sale by its U.S. parent Cardinal Health with a price of about £150 million ($242
Cardinal plots spinoff, CEO switch
Drug distributor Cardinal Health plans to spin off its clinical and medical products divisions into one new public company. Cardinal Chairman and CEO Kerry Clark will stick around through the
